Jazz Pharmaceuticals – $575 Million Exchangeable Senior Note Offering

San Francisco – September 22, 2017 – Cooley advised Jazz Pharmaceuticals plc on its completed Rule 144A offering of $575 million aggregate principal amount of 1.50% exchangeable senior notes due 2024 issued by its wholly-owned subsidiary, Jazz Investments I Limited. This offering also included the full exercise of the initial purchasers’ option to purchase up to an additional $75 million aggregate principal amount of notes. Chad Mills, Rob Phillips, Charlie Kim and Mischi a Marca led the Cooley team advising Jazz.

Jazz Pharmaceuticals (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs.

Cooley recently advised Jazz Pharmaceuticals on its strategic agreement with ImmunoGen.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.